Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00630656 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis
A Phase 2 study, sponsored by Agennix.
- Completed
- Registry status
- Phase 2
- Development phase
- 190
- Enrollment target
NCT00630656: Completed Phase 2 study, sponsored by Agennix.
NCT00630656 is a Phase 2 study that has completed, run by Agennix. The registered enrollment target is 190 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00630656, a Phase 2 study, has completed, sponsored by Agennix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 190 participants
- Enrollment target
Study Summary
Study will evaluate the safety and potential benefit of recombinant human talactoferrin as an addition to the standard care of severe sepsis.
Interventions
- DRUG Placebo
- DRUG Talactoferrin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
What the finished NCT00630656 record still lists
NCT00630656 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00630656 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00630656 about?
NCT00630656 is a clinical study titled "Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis". Study will evaluate the safety and potential benefit of recombinant human talactoferrin as an addition to the standard care of severe sepsis.
What is the current status of trial NCT00630656?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2008-04. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00630656?
The interventions under investigation include: Placebo (DRUG), Talactoferrin alfa (DRUG).
Who is sponsoring clinical trial NCT00630656?
This trial is sponsored by Agennix, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00630656's enrollment target sits among peer trials
190 353rd of 2000 higher than 1,646 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03257033 · 190 participants · Phase 3
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- NCT03642028 · 190 participants · Phase 4
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
- NCT04015609 · 190 participants · NA
Psychotherapy Intervention for Latinos With Advanced Cancer
- NCT04284397 · 190 participants · Early Phase 1
Identification of Critical Thermal Environments for Aged Adults
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia